Results 181 to 190 of about 14,494 (232)

Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers

Clinical Pharmacology in Drug Development, 2023
Tenofovir alafenamide fumarate (TAF) is a first‐line drug for treating hepatitis B virus infection. This study aimed to establish the prodrug–metabolite population pharmacokinetic (PK) model for TAF and its metabolite tenofovir (TFV) in healthy Chinese ...
Xingfang Ji, Yunfei Li, Zhipeng Wang, Yuan Gao, Ling Wang   +4 more
semanticscholar   +3 more sources

Tenofovir Alafenamide Fumarate-Associated Fanconi Syndrome

Journal of the American Society of Nephrology
M. Hanson, Basant Sanad, Jae H. Kim
semanticscholar   +2 more sources

Effectiveness and safety of tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe.

International Journal of Antimicrobial Agents
OBJECTIVE Effectiveness and safety outcomes were compared between those on tenofovir alafenamide fumarate (TAF), tenofovir disoproxil fumarate (TDF) or abacavir (ABC), among children and young people living with HIV (CYPLHIV) aged 6-0·500), although ...
E. Chappell
semanticscholar   +1 more source

Tenofovir alafenamide fumarate for the treatment of HIV infection

Drugs of Today, 2016
Tenofovir alafenamide fumarate is a recently developed prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor with potent inhibitory activity against HIV. The utility of a previously developed tenofovir prodrug, tenofovir disoproxil fumarate, had been hampered by renal and bone mineral adverse events. Tenofovir alafenamide fumarate
R, Sampath, J, Zeuli, S, Rizza, Z, Temesgen   +3 more
openaire   +2 more sources

Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam

Antiviral Therapy
Background This study aims to evaluate the cost-effectiveness of tenofovir alafenamide fumarate (TAF) versus tenofovir disoproxil fumarate (TDF) for chronic hepatitis B treatment from a payer’s perspective in a limited-income context like Vietnam ...
T. Thuy, N.T. Ha, Do Duy Cuong, Le Van Long, N. Q. Anh   +4 more
semanticscholar   +1 more source

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study

Expert Review of Anti-Infective Therapy, 2023
Background This study aimed to evaluate the therapeutic effect and tolerance of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) use for 24 weeks in anti-retroviral therapy (ART)-naïve patients in China.
Linguang Gan, Xiaoxin Xie, Yanhua Fu, Yebing Song, Chunli Song, Tingting Ren, Hai Long   +6 more
semanticscholar   +1 more source

Dolutegravir/lamivudine versus bictegravir/ emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of effectiveness and weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON).

International Journal of Infectious Diseases
BACKGROUND Among people living with HIV (PWH), the use of integrase strand transfer inhibitors (INSTIs) has been increasingly linked to notable weight gain, raising clinical concern.
Chia-Jui Yang, Linghua Li, Qingxia Zhao, Wen-Hsin Hsih, Mao-Wang Ho, Tsung-Chia Chen, M. Tsai, Shu-Yuan Lee, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Xue Zhang, Meiyin Zou, Yi-Wen Wu, Miao-Hui Huang, Tung-Che Hung, Hsin-Hao Lai, Ping Ma, Chien- Yu Cheng   +18 more
semanticscholar   +1 more source

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for people with ultra-high viral load of HIV-1: a retrospective real-world cohort study

Frontiers in Virology
This study evaluated the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in treatment-naïve adults with HIV-1 and an ultra-high viral load (uVL; HIV-1 RNA ≥500,000 copies/mL)—a population at high risk for ...
Xiang He, Xiaoxin Xie, Yanhua Fu, Jinhong He, Xin Luo, Hai Long   +5 more
semanticscholar   +1 more source

Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B

Hepatology Research, 2023
Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are considered safe nucleoside/nucleotide analogs (NA) for the kidney. This study aimed to investigate the long‐term effects of ETV or TAF on renal function in elderly patients with chronic ...
Misako Tanaka, Takemi Akahane, H. Kawaratani, Nobuyuki Yorioka, Aritoshi Koizumi, Shohei Asada, Takuya Matsuda, Satoshi Iwai, Y. Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, K. Kaji, T. Namisaki, Hitoshi Yoshiji   +14 more
semanticscholar   +1 more source

Comparing the efficacy and safety of a first line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.

International Journal of Antimicrobial Agents, 2023
BACKGROUND In the last decade, first-line Integrase strand transfer inhibitors (INSTI) based regimens have become commonly used in clinical practice. We aimed to analyze and compare the efficacy and safety of bictegravir (BIC) and dolutegravir (DTG) when
A. Ciccullo, G. Baldin, V. Borghi, L. Oreni, F. Lagi, P. Fusco, Andrea Giacomelli, Carlo Torti, G. Sterrantino, C. Mussini, Spinello Antinori, S. Giambenedetto   +11 more
semanticscholar   +1 more source